Xvivo Perfusion Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Christoffer Rosenblad
Chief executive officer
SEK 5.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.6yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 43% Undervaluation?
Dec 06
Xvivo Perfusion (STO:XVIVO) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 04Results: Xvivo Perfusion AB (publ) Beat Earnings Expectations And Analysts Now Have New Forecasts
Oct 27With Xvivo Perfusion AB (publ) (STO:XVIVO) It Looks Like You'll Get What You Pay For
Oct 25Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 40% Undervaluation?
Aug 03Xvivo Perfusion AB (publ) (STO:XVIVO) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Apr 25There Are Reasons To Feel Uneasy About Xvivo Perfusion's (STO:XVIVO) Returns On Capital
Apr 11Need To Know: Analysts Just Made A Substantial Cut To Their Xvivo Perfusion AB (publ) (STO:XVIVO) Estimates
Feb 05We Think That There Are Issues Underlying Xvivo Perfusion's (STO:XVIVO) Earnings
Feb 01Earnings Beat: Xvivo Perfusion AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jan 28Returns On Capital At Xvivo Perfusion (STO:XVIVO) Have Stalled
Aug 24Why Xvivo Perfusion AB (publ) (STO:XVIVO) Could Be Worth Watching
Jul 17Do Xvivo Perfusion's (STO:XVIVO) Earnings Warrant Your Attention?
Jun 16Xvivo Perfusion (STO:XVIVO) May Have Issues Allocating Its Capital
Apr 19Are Investors Undervaluing Xvivo Perfusion AB (publ) (STO:XVIVO) By 21%?
Mar 23With EPS Growth And More, Xvivo Perfusion (STO:XVIVO) Makes An Interesting Case
Mar 07When Should You Buy Xvivo Perfusion AB (publ) (STO:XVIVO)?
Feb 13Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital
Dec 14Is There An Opportunity With Xvivo Perfusion AB (publ)'s (STO:XVIVO) 35% Undervaluation?
Nov 17Xvivo Perfusion (STO:XVIVO) Might Be Having Difficulty Using Its Capital Effectively
Aug 20Statutory Profit Doesn't Reflect How Good Xvivo Perfusion's (STO:XVIVO) Earnings Are
Jul 21Be Wary Of Xvivo Perfusion (STO:XVIVO) And Its Returns On Capital
Mar 30At kr258, Is Xvivo Perfusion AB (publ) (STO:XVIVO) Worth Looking At Closely?
Feb 18A Look At The Fair Value Of Xvivo Perfusion AB (publ) (STO:XVIVO)
Jan 30CEO
Christoffer Rosenblad (49 yo)
3yrs
Tenure
SEK 5,031,000
Compensation
Mr. Christoffer Rosenblad serves as Chief Executive Officer at Xvivo Perfusion AB (publ) since November 30, 2022. He served as Deputy Chief Executive Officer and Global Business Development & Service Direc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 3yrs | SEK 5.03m | 0.16% SEK 25.2m | |
| Chief Financial Officer | 4.2yrs | no data | 0.0085% SEK 1.3m | |
| COO & Deputy CEO | 2.1yrs | no data | 0.0063% SEK 980.1k | |
| Senior Vice President of Human Resources | 2yrs | no data | no data | |
| Senior Advisor | 4.6yrs | SEK 1.62m | no data | |
| Senior Vice President of Quality Assurance and Regulatory Affairs Europe & RoW | no data | no data | 0.0086% SEK 1.3m | |
| Chief Medical Officer | 4.3yrs | no data | 0.011% SEK 1.7m | |
| Senior Vice President of Commercial Europe & RoW | 4.3yrs | no data | 0.012% SEK 1.8m | |
| Senior Vice President of Clinical & Regulatory Affairs North America | no data | no data | no data | |
| Senior Vice President of North America | less than a year | no data | no data |
3.6yrs
Average Tenure
54yo
Average Age
Experienced Management: XVIVO's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 12yrs | SEK 440.00k | 0.015% SEK 2.3m | |
| Independent Director | 4.3yrs | no data | 0.0076% SEK 1.2m | |
| Independent Director | 1.8yrs | no data | 0.18% SEK 27.6m | |
| Independent Director | 8.7yrs | SEK 130.00k | 0.0034% SEK 527.9k | |
| Independent Director | 4.3yrs | no data | 0.0041% SEK 637.5k | |
| Independent Director | 2.8yrs | no data | no data |
4.3yrs
Average Tenure
63.5yo
Average Age
Experienced Board: XVIVO's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 02:07 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xvivo Perfusion AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dylan van Haaften | Bryan Garnier & Co |
| Maria Vara Fernández | Bryan Garnier & Co |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |